AC-262 Accadrine Research Overview
AC-262, also known as AC-262536 or Accadrine, is a selective androgen receptor modulator researched within the wider SARM category. It is discussed as a non-steroidal androgen receptor ligand, meaning its main research interest is linked to androgen receptor binding, receptor activation, tissue-selective signalling and marker-based pathway analysis.
AC-262 is not a peptide. It belongs to the small-molecule SARM research category, where compounds are studied for how they interact with androgen receptor pathways rather than peptide receptor systems such as GHRH, GLP-1, GIP, glucagon or ghrelin receptors.
A published pharmacological characterisation study describes AC-262536 as a potent and selective androgen receptor ligand with partial agonist activity compared with testosterone in functional cell-based assay work. The same study also examined AC-262536 in preclinical anabolic marker models, making it one of the lesser-known but scientifically interesting compounds within androgen receptor research.
What is AC-262 Accadrine
AC-262 is most commonly discussed under the name AC-262536. The name Accadrine is also used online for the same research compound.
Key research identifiers include:
Compound name: AC-262536
Common name: AC-262
Alternative name: Accadrine
Compound class: Selective androgen receptor modulator
Research category: Non-steroidal SARM
Primary pathway: Androgen receptor signalling
Main research focus: Receptor selectivity, partial agonist behaviour and tissue marker response
The most important point is that AC-262 is a SARM, not a peptide. SARMs are researched because they interact with androgen receptors and may show different signalling profiles across tissue models.
This makes AC-262 different from compounds such as MK-677, which is studied through ghrelin receptor signalling, and different from peptide compounds such as CJC-1295, Ipamorelin, Sermorelin or BPC-157.
AC-262 and androgen receptor signalling
The androgen receptor is a nuclear receptor. When an androgen receptor ligand binds to it, the receptor can change shape, move into the nucleus and influence gene transcription.
In research terms, this means AC-262 may be studied through:
androgen receptor binding
partial agonist activity
transcriptional signalling
co-regulator recruitment
anabolic marker pathways
bone marker response
muscle marker models
prostate marker comparison
endocrine feedback markers
tissue-selective pathway analysis
The androgen receptor does not act like a simple on/off switch. Different ligands can create different receptor shapes, different co-regulator interactions and different marker-level responses. This is one reason SARM research can be complex.
AC-262 is especially interesting because published research describes it as having partial agonist activity. That means it may activate the androgen receptor pathway differently from a full agonist in certain assay systems.
Why AC-262 is called a SARM
AC-262 is called a SARM because it belongs to the selective androgen receptor modulator category.
The word “selective” is important. It does not mean a compound only acts in one tissue or produces one simple outcome. It means researchers are interested in how the compound modulates androgen receptor signalling across different tissues and marker systems.
SARM research often focuses on whether a compound can show a different balance between anabolic marker activity and androgenic marker activity when compared with older androgen receptor ligands.
For AC-262, the research discussion is mainly around:
androgen receptor selectivity
partial agonist behaviour
non-steroidal structure
anabolic marker response
tissue-selective activity
comparative receptor assays
preclinical marker studies
This places AC-262 in the same broad research category as compounds such as Ostarine, Ligandrol, RAD-140 and Andarine, while still giving it its own distinct profile.
How AC-262 works in research
AC-262 is studied as an androgen receptor ligand. In functional assay systems, researchers can examine how strongly it activates androgen receptor signalling, how it compares with reference androgens, and whether it shows selectivity across receptor systems.
A simplified research pathway may look like this:
AC-262 binds to the androgen receptor
the receptor changes shape
the receptor complex influences transcriptional activity
androgen-responsive genes may be affected
marker panels are measured
tissue-specific differences are compared
This is why AC-262 research is not just about one marker. It is about receptor binding, functional activation, tissue response and marker interpretation.
The published pharmacological characterisation of AC-262536 reported selective androgen receptor activity and partial agonist behaviour in assay work, supporting its placement within SARM research.
AC-262 and partial agonist activity
Partial agonist activity is one of the key themes in AC-262 research.
A full agonist can strongly activate a receptor pathway when it binds. A partial agonist can activate the same receptor pathway, but with a lower maximum response in a given assay system.
This matters because partial agonists can sometimes create different biological marker patterns from full agonists. In androgen receptor research, this can affect how scientists compare compounds across tissue models.
For AC-262, partial agonist behaviour may be reviewed through:
androgen receptor activation levels
transcriptional response assays
comparative ligand activity
reference androgen comparison
anabolic marker response
tissue selectivity studies
endocrine feedback markers
This does not mean AC-262 is weak or simple. It means its receptor behaviour should be studied carefully using proper assay design and marker interpretation.
AC-262 and tissue-selective research
Tissue selectivity is one of the biggest reasons SARMs are researched. Androgen receptors are found across different tissue systems, but receptor behaviour can vary depending on the ligand, tissue type, co-regulator environment and cellular context.
AC-262 may be discussed in tissue-selective research connected with:
muscle marker response
bone marker response
prostate marker comparison
anabolic pathway markers
androgenic pathway markers
endocrine feedback markers
gene expression panels
receptor activation differences
The aim is to understand how a non-steroidal androgen receptor ligand behaves across different models.
This is important because a compound can be selective in one assay or model, but still require broader study across multiple systems. Good research interpretation should avoid overclaiming from one marker or one study.
AC-262 and anabolic marker models
AC-262 appears in research discussions around anabolic marker activity because androgen receptor signalling is connected with tissue maintenance, protein turnover and growth-related pathways.
In research models, anabolic marker review may include:
lean tissue marker panels
protein synthesis pathway markers
nitrogen balance models
myogenic gene expression
tissue weight markers in preclinical models
muscle-associated transcriptional markers
comparative anabolic-to-androgenic marker ratios
The published pharmacological characterisation study reported that AC-262536 improved anabolic parameters in a preclinical castrated male rat model, including markers connected with levator ani tissue response and luteinising hormone suppression.
This should be understood as controlled preclinical research, not as customer-facing outcome language. AC-262 should be discussed through receptor science, tissue models and marker-based interpretation.
AC-262 and bone marker research
Androgen receptor signalling can also be studied in relation to bone marker pathways. SARMs are often researched because androgen receptor modulation may show different responses across skeletal and soft tissue models.
AC-262 research may be discussed in relation to:
bone turnover markers
skeletal tissue marker response
osteoblast pathway models
mineralisation-related markers
androgen receptor activity in bone models
tissue-selective comparison studies
This type of research helps scientists understand how androgen receptor ligands behave outside one narrow tissue model. For SARM research, bone marker studies can be important because they help show whether a compound has broader tissue pathway relevance.
AC-262 and endocrine marker research
Because AC-262 interacts with androgen receptor signalling, it can also be relevant to endocrine feedback research.
Androgen receptor activity connects with wider endocrine systems, so researchers may examine:
luteinising hormone markers
follicle-stimulating hormone markers
testosterone pathway markers
hypothalamic-pituitary-gonadal axis signalling
feedback loop response
time-course marker changes
comparative SARM response
The published AC-262536 characterisation study included luteinising hormone suppression within its preclinical findings.
This makes endocrine feedback an important part of AC-262 research interpretation. It should not be viewed only as an anabolic marker compound. Its wider pathway behaviour matters.
AC-262 compared with RAD-140
AC-262 and RAD-140 both belong to the SARM category, but they should not be treated as identical.
RAD-140, also known as Testolone, is often discussed as a strong androgen receptor research compound. AC-262 is often discussed for its selective androgen receptor binding and partial agonist behaviour.
A research comparison may include:
androgen receptor affinity
partial agonist versus stronger agonist profile
tissue marker response
endocrine feedback markers
anabolic marker panels
off-target receptor screening
preclinical study design
analytical identity testing
AC-262 may be especially useful in research discussions where partial agonist behaviour is the focus. RAD-140 is usually discussed more heavily in relation to strong androgen receptor activation and tissue-selective SARM research.
AC-262 compared with MK-677
AC-262 and MK-677 are sometimes grouped together online because both appear in SARMs and research compound categories. Scientifically, they are very different.
AC-262 is a selective androgen receptor modulator.
MK-677 is not a SARM. It is a growth hormone secretagogue researched through the ghrelin receptor / GHSR pathway.
The difference is clear:
AC-262: androgen receptor signalling
MK-677: ghrelin receptor signalling
AC-262: SARM category
MK-677: growth hormone secretagogue category
AC-262: transcriptional androgen receptor markers
MK-677: GH axis and IGF-1 marker research
This matters because product education should be accurate. AC-262 should be explained through androgen receptor science, not GH secretagogue pathways.
AC-262 and analytical testing
AC-262 is a small-molecule research compound, so analytical testing is important for identity and purity review.
Testing methods may include:
HPLC purity analysis
LC-MS identity confirmation
NMR structural review
quantity testing
impurity profiling
batch documentation
COA review
HPLC can be used to assess purity, while LC-MS can help support molecular identity by reviewing mass-related data. COA documentation may provide batch-specific information depending on the supplier, test method and available records.
For research-focused product education, analytical testing helps connect the product name to the material being supplied.
AC-262 research interpretation
AC-262 should be interpreted through receptor-level and marker-level data.
Important research interpretation points include:
which receptor assay was used
whether partial agonist activity was measured
which comparator ligand was used
which tissue model was studied
whether endocrine markers were included
whether anabolic marker panels were reviewed
whether time-course data was available
whether off-target receptor screening was included
A single result does not explain the full compound profile. AC-262 research is strongest when androgen receptor binding, functional activation, tissue response and endocrine marker data are considered together.
AC-262 research summary
AC-262 Accadrine is best understood as a non-steroidal selective androgen receptor modulator researched for androgen receptor binding, partial agonist behaviour, tissue-selective marker response and endocrine feedback pathways.
Its main research themes include:
androgen receptor activation
partial agonist activity
SARM selectivity
anabolic marker models
bone marker research
endocrine feedback markers
tissue-selective signalling
analytical purity testing
small-molecule classification
AC-262 should not be confused with peptides, GLP-1 receptor agonists, GHRH analogues or growth hormone secretagogues. Its main scientific identity is androgen receptor pathway research.
Conclusion
AC-262, also known as AC-262536 or Accadrine, is a non-steroidal selective androgen receptor modulator researched through androgen receptor signalling. It is not a peptide and does not belong to growth hormone secretagogue, GHRH, GLP-1, GIP, glucagon or ghrelin receptor categories.
The main research interest in AC-262 is its androgen receptor activity, selective receptor profile and partial agonist behaviour. Published pharmacological characterisation describes AC-262536 as a potent and selective androgen receptor ligand with partial agonist activity in functional assay work, placing it firmly within SARM research.
AC-262 research may include androgen receptor binding, transcriptional activation, anabolic marker models, bone marker research, endocrine feedback markers, tissue-selective pathway studies and analytical identity testing.
Correct classification matters. AC-262 should be described as a selective androgen receptor modulator, not as a peptide or growth hormone-related compound. This keeps research education clear and avoids confusion across BioPlex Peptides product categories.
For research-focused discussion, AC-262 is valuable because it gives scientists another compound for studying androgen receptor modulation, partial agonist signalling and marker-based SARM pathway analysis.
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
AC-262 Accadrine
View AC-262 Accadrine Research Compound at BioPlex Peptides ⟶
SARMs Research Compounds
View BioPlex Peptides SARMs research compounds ⟶
All discussion is presented strictly for educational and scientific research purposes only, supporting informed study, data interpretation, and responsible laboratory investigation.
